COSMOS Pharmaceutical Corporation
CSMYF · OTC
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Revenue | $1,852 | $259,122 | $246,332 | $244,095 |
| % Growth | -99.3% | 5.2% | 0.9% | – |
| Cost of Goods Sold | $1,463 | $205,049 | $193,198 | $192,584 |
| Gross Profit | $389 | $54,073 | $53,134 | $51,511 |
| % Margin | 21% | 20.9% | 21.6% | 21.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $107 | $0 | $0 |
| SG&A Expenses | $310 | $24,506 | $42,194 | $42,635 |
| Sales & Mktg Exp. | $0 | $1,561 | $0 | $0 |
| Other Operating Expenses | $0 | $20,791 | -$343 | $112 |
| Operating Expenses | $310 | $45,297 | $41,851 | $42,747 |
| Operating Income | $79 | $8,776 | $11,283 | $8,764 |
| % Margin | 4.3% | 3.4% | 4.6% | 3.6% |
| Other Income/Exp. Net | $3 | $410 | $460 | $613 |
| Pre-Tax Income | $82 | $9,186 | $11,743 | $9,377 |
| Tax Expense | $27 | $551 | $3,828 | $3,092 |
| Net Income | $56 | $8,635 | $7,915 | $6,285 |
| % Margin | 3% | 3.3% | 3.2% | 2.6% |
| EPS | 0.7 | 108.95 | 99.86 | 79.3 |
| % Growth | -99.4% | 9.1% | 25.9% | – |
| EPS Diluted | 0.7 | 108.95 | 99.86 | 79.3 |
| Weighted Avg Shares Out | 79 | 79 | 79 | 79 |
| Weighted Avg Shares Out Dil | 79 | 79 | 79 | 79 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $12 | $0 | $0 |
| Interest Expense | $1 | $109 | $34 | $37 |
| Depreciation & Amortization | $39 | $6,013 | $4,981 | $5,293 |
| EBITDA | $122 | $15,306 | $15,921 | $14,169 |
| % Margin | 6.6% | 5.9% | 6.5% | 5.8% |